Evidence from the Breast Cancer Customization Project suggests that a more comprehensive approach is needed to help patients find the motivation to adopt an active lifestyle. Physical activity is often recommended by clinicians as a lifestyle intervention to help prevent and manage non-communicable diseases, including cancer. It is also essential for the quality of life of patients diagnosed with cancer.

Gastrointestinal stromal tumors (GIST) are mesenchymal tumors driven by mutations in oncogenes. In recent years, various types of small-molecule tyrosine kinase inhibitors (TKIs) have provided new treatment options for patients with advanced GIST, but there remains a significant unmet need in clinical care. During the 2024 ESMO Annual Meeting, Dr. Jian Li's team from Peking University Cancer Hospital presented updated data from the follow-up treatment analysis of the INTRIGUE China bridging study on ripretinib, offering further insights into the clinical application of such novel drugs.

With the rapid development of genetic testing technology, the treatment strategies for patients with cancer of unknown primary (CUP) are undergoing revolutionary changes. During the 2024 ESMO Congress, the World CUP Alliance held a special "Roundtable on Access & Awareness of Precision Oncology" at the ESMO Congress, looking forward to the current treatment of CUP patients. After the meeting, Oncology Frontier specially invited Prof. Xichun Hu from Fudan University Shanghai Cancer Center, Prof. Linda Mileshkin from Peter MacCallum Cancer Center in Australia, Prof. Manel Esteller from Josep Carreras Leukemia Research Institute in Spain, and Prof. Qinghua Xu from Hangzhou Gene Help Technology Co., Ltd Help to gather together and discuss in depth the new advances in the treatment of CUP. From the positive data of the CUPISCO trial to the results of the Fudan CUP-001 study, the experts not only shared cutting-edge research results but also proposed valuable insights on how to improve the diagnostic accuracy for CUP patients and promote the implementation of personalized treatment plans, bringing new treatment hopes for CUP patients worldwide.

New data shows that breastfeeding does not increase the risk of breast cancer recurrence or developing secondary breast cancer, nor does it pose any health risks to the child.

With the rapid advancement of science and technology, there is growing hope that more cancers can be intercepted at their earliest stages. The European Society for Medical Oncology (ESMO) is deeply exploring the field of prevention to ensure that oncologists are educated and guided in this evolving area.

From September 13 to 17, the 2024 ESMO Annual Meeting is in full swing in Barcelona, Spain. Oncology Frontier is attending the event and bringing you first-hand insights from the conference. During the non-metastatic non-small cell lung cancer (NSCLC) paper session held on September 13, Dr. Suresh Senan from Amsterdam, Netherlands, presented the latest results from the ADRIATIC study, where subgroup analysis further supports previous practice-changing findings.